New research looks at odd effects from some NSAID use
Yale University
Non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and aspirin are widely used to treat pain and inflammation.
Now,
a new Yale-led study has uncovered a previously unknown process by which some
NSAIDs affect the body. The finding may explain why similar NSAIDs produce a
range of clinical outcomes and could inform how the drugs are used in the
future.
The
study was published May 23 in the journal Immunity.
Until
now, the anti-inflammatory effects of NSAIDs were believed to arise solely
through the inhibition of certain enzymes. But this mechanism does not account
for many clinical outcomes that vary across the family of drugs. For example,
some NSAIDs prevent heart disease while others cause it, some NSAIDs have been
linked to decreased incidence of colorectal cancer, and various NSAIDs can have
a wide range of effects on asthma.
Now,
using cell cultures and mice, Yale researchers have uncovered a distinct
mechanism by which a subset of NSAIDs reduce inflammation. And that mechanism
may help explain some of these curious effects.
The
research showed that only some NSAIDs -- including indomethacin, which is used
to treat arthritis and gout, and ibuprofen -- also activate a protein called
nuclear factor erythroid 2-related factor 2, or NRF2, which, among its many
actions, triggers anti-inflammatory processes in the body.
"It's interesting and exciting that NSAIDs have a different mode of action than what was known previously," said Anna Eisenstein, an instructor at the Yale School of Medicine and lead author of the study. "And because people use NSAIDs so frequently, it's important we know what they're doing in the body."
The
research team can't say for sure that NSAIDs' unexpected effects are due to
NRF2 -- that will require more research. "But I think these findings are
suggestive of that," Eisenstein said.
Eisenstein
is now looking into some of the drugs' dermatological effects -- causing
rashes, exacerbating hives, and worsening allergies -- and whether they are
mediated by NRF2.
This
discovery still needs to be confirmed in humans, the researchers note. But if
it is, the findings could have impacts on how inflammation is treated and how
NSAIDs are used.
For
instance, several clinical trials are evaluating whether NRF2-activating drugs
are effective in treating inflammatory diseases like Alzheimer's disease,
asthma, and various cancers; this research could inform the potential and
limitations of those drugs. Additionally, NSAIDs might be more effectively
prescribed going forward, with NRF2-activating NSAIDs and non-NRF2-activating
NSAIDs applied to the diseases they're most likely to treat.
The
findings may also point to entirely new applications for NSAIDs, said
Eisenstein.
NRF2
controls a large number of genes involved in a wide range of processes,
including metabolism, immune response, and inflammation. And the protein has
been implicated in aging, longevity, and cellular stress reduction.
Said Eisenstein, "That NRF2 does so much suggests that NSAIDs might have other effects, whether beneficial or adverse, that we haven't yet looked for."